ECCO 2023

New molecules on the horizon!

A focus on surgery and post-operative maintenance

JAK inhibitors - small molecules to treat IBD

Upadacitinib is efficacious for UC regardless of…

Long-term extension of ustekinumab in UC

Latest update on JAK inhibition

Prolonged treatment with Ozanimod recaptures remission…

S1P modulators in UC

Long-term duration of response with ozanimod in UC

No impact of previous therapies for Upadacitinib in…

Mucosal healing induced by vedolizumab in chronic…

Medium-term outcome of IBD patients diagnosed at…

Upadacitinib for fistulizing Crohn´s disease?

Vedolizumab heals pouch mucosa

Lang Termijn respons met ozanimod bij colitis ulcerosa

S1P-Modulatoren bei Colitis ulcerosa

Upadacitinib is efficient bij colitis ulcerosa,…

Studio lungo termine di ustekinumab in UC

Update zu JAK-Inhibitoren bei CED

Il prolungamento del trattamento con Ozanimod induce…

Η μεσοπρόθεσμη έκβαση ασθενών με ΙΦΝΕ που…

New aspects on safety of anti-TNF treatment

Safety update on JAKis - new worries?

S1P-modulators: a spotlight on safety

Etrasimod shows fast stool frequency and rectal…

Positive effects of Upadacitinib on resolution of…

Ileostomy with better prognosis than pouch in PSC

Ozanimod shows good efficacy and safety profile in UC…

Les antibiotiques dans la petite enfance augmentent le…

Το upadacitinib επιφέρει ύφεση των κοιλιακών…

Ozanimod shows good efficacy and safety profile after…

Ileostomie mit besserer Prognose als Pouch bei PSC

Practice-changing data on surgery in CD and UC

Peri- and postoperative management of CD

Surgical and post-operative management in CD

Early treatment with biologics in IBD

DNA methylation predicts response to biologics in IBD

Ileocaecal Crohn's disease - should we call the surgeon…

Enteral nutrition - food for thought!

Surgery in CD - resetting or not?

Another clue for the role of the microbiome in PSC?

Timing of surgery in Crohn's disease

Epigenetic fingerprinting - a novel tool for precision…

Is it feasible to stop anti-TNF treatment in…

Vedolizumab for preventing postoperative reccurence of…

Vedolizumab prevents postoperative recurrence in CD

New drugs on the block!

Biologics in CD – is earlier better?

Post-surgical Crohn's disease

Neue Substanzen!

Chirurgischer Verlauf nach Morbus Crohn

Είναι ευχερές να διακόψουμε τους αντι-TNF παράγοντες…

Résection chirurgicale au course de la maladie de…

Vedolizumab en prévention de la récidive postopératoire…

Postać ileocekalna choroby Crohna - czy chirurgia ma…

Vedolizumab previene la recidiva post operatoria nei…

Another clue for the role of the microbiome in PSC?

Biosimilars

Aanpak van de (post)operatieve Crohn patient

Résection chirurgicale précoce dans la MC

Epigenetic Fingerprinting - ein neues Werkzeug für die…

Biologics in CD - is earlier better?

Histology - a new therapeutic target in UC?

Comprehensive Disease Control

Our patients will be better off in the near future!

GPX4 fueling postoperative recurrence in Crohn's…

Sequencing in IBD - congress overview

Mucosal signatures suggest a mechanism for early CD…

New ECCO guidelines on extraintestinal manifestations…

New opportunities from the application of artificial…

Nuove opportunità dall’applicazione dell’intelligenza…

Mucosal signatures suggest a mechanism for early CD…

Sequencing nelle malattie infiammatorie cronicale…

Panoramica completa sulla chirurgia nelle malattie…

GPX4 fördert postoperatives Morbus Crohn Rezidiv

Nowe wytyczne ECCO dotyczące manifestacji…